(IFF) International Flavors - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 18.816m USD | Total Return: 1.8% in 12m
Avg Turnover: 122M
EPS Trend: 68.8%
Qual. Beats: 0
Rev. Trend: -88.6%
Qual. Beats: 4
Warnings
Altman Z'' -0.16 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Garp
International Flavors & Fragrances Inc. (IFF) is a global manufacturer of specialty ingredients used across the food, beverage, health, and personal care industries. The company operates through four primary segments: Taste, Food Ingredients, Health & Biosciences, and Scent. Its product portfolio ranges from savory seasonings and beverage compounds to enzymes, probiotics, and fragrance molecules used in consumer goods.
The company operates within the specialty chemicals sector, where business models rely heavily on research and development to create proprietary formulations for consumer packaged goods (CPG) companies. These ingredients often represent a small fraction of a finished products total cost but are critical to its sensory profile and functional performance. IFF typically utilizes long-term supply contracts, integrating its ingredients into the global supply chains of major food and cosmetic brands.
Investors can evaluate the companys historical performance metrics and valuation multiples on ValueRay to gain deeper insights. Founded in 1909 and headquartered in New York, IFF maintains a significant international footprint, providing essential inputs for diverse applications including animal nutrition, grain processing, and natural food preservation.
- Raw material cost volatility impacts gross margins across all four business segments
- Consumer demand for natural and plant-based ingredients drives volume growth
- Strategic divestitures and debt reduction initiatives influence long-term shareholder valuation
- Global research and development spending determines competitive advantage in proprietary scent molecules
- High interest rates increase the cost of servicing significant long-term debt obligations
| Net Income: 839.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.42 > 1.0 |
| NWC/Revenue: 16.61% < 20% (prev 35.23%; Δ -18.62% < -1%) |
| CFO/TA 0.04 > 3% & CFO 980.0m > Net Income 839.0m |
| Net Debt (5.87b) to EBITDA (1.94b): 3.04 < 3 |
| Current Ratio: 1.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (257.0m) vs 12m ago 0.39% < -2% |
| Gross Margin: 35.10% > 18% (prev 0.36%; Δ 3.47k% > 0.5%) |
| Asset Turnover: 40.40% > 50% (prev 40.43%; Δ -0.03% > 0%) |
| Interest Coverage Ratio: 5.26 > 6 (EBITDA TTM 1.94b / Interest Expense TTM 202.0m) |
| A: 0.07 (Total Current Assets 5.44b - Total Current Liabilities 3.65b) / Total Assets 25.14b |
| B: -0.13 (Retained Earnings -3.35b / Total Assets 25.14b) |
| C: 0.04 (EBIT TTM 1.06b / Avg Total Assets 26.70b) |
| D: -0.44 (Book Value of Equity -4.83b / Total Liabilities 10.99b) |
| Altman-Z'' = -0.16 = B |
| DSRI: 1.02 (Receivables 1.83b/1.89b, Revenue 10.79b/11.43b) |
| GMI: 1.03 (GM 35.10% / 36.18%) |
| AQI: 1.16 (AQ_t 0.62 / AQ_t-1 0.54) |
| SGI: 0.94 (Revenue 10.79b / 11.43b) |
| TATA: -0.01 (NI 839.0m - CFO 980.0m) / TA 25.14b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
Over the past week, the price has changed by +2.98%, over one month by +5.77%, over three months by -7.92% and over the past year by +1.84%.
- StrongBuy: 10
- Buy: 7
- Hold: 4
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 91.6 | 21.7% |
P/E Forward = 16.2338
P/S = 1.7441
P/B = 1.3217
P/EG = 0.8417
Revenue TTM = 10.79b USD
EBIT TTM = 1.06b USD
EBITDA TTM = 1.94b USD
Long Term Debt = 4.74b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 6.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 618.0m
Net Debt = 5.87b USD (calculated: Debt 6.43b - CCE 562.0m)
Enterprise Value = 24.69b USD (18.82b + Debt 6.43b - CCE 562.0m)
Interest Coverage Ratio = 5.26 (Ebit TTM 1.06b / Interest Expense TTM 202.0m)
EV/FCF = 61.72x (Enterprise Value 24.69b / FCF TTM 400.0m)
FCF Yield = 1.62% (FCF TTM 400.0m / Enterprise Value 24.69b)
FCF Margin = 3.71% (FCF TTM 400.0m / Revenue TTM 10.79b)
Net Margin = 7.78% (Net Income TTM 839.0m / Revenue TTM 10.79b)
Gross Margin = 35.10% ((Revenue TTM 10.79b - Cost of Revenue TTM 7.00b) / Revenue TTM)
Gross Margin QoQ = 37.14% (prev 29.20%)
Tobins Q-Ratio = 0.98 (Enterprise Value 24.69b / Total Assets 25.14b)
Interest Expense / Debt = 0.68% (Interest Expense 44.0m / Debt 6.43b)
Taxrate = 18.66% (39.0m / 209.0m)
NOPAT = 864.6m (EBIT 1.06b * (1 - 18.66%))
Current Ratio = 1.49 (Total Current Assets 5.44b / Total Current Liabilities 3.65b)
Debt / Equity = 0.46 (Debt 6.43b / totalStockholderEquity, last quarter 14.12b)
Debt / EBITDA = 3.04 (Net Debt 5.87b / EBITDA 1.94b)
Debt / FCF = 14.68 (Net Debt 5.87b / FCF TTM 400.0m)
Total Stockholder Equity = 14.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.14% (Net Income 839.0m / Total Assets 25.14b)
RoE = 4.77% (Net Income TTM 839.0m / Total Stockholder Equity 17.58b)
RoCE = 4.76% (EBIT 1.06b / Capital Employed (Equity 17.58b + L.T.Debt 4.74b))
RoIC = 3.93% (NOPAT 864.6m / Invested Capital 22.02b)
WACC = 6.14% (E(18.82b)/V(25.25b) * Re(8.05%) + D(6.43b)/V(25.25b) * Rd(0.68%) * (1-Tc(0.19)))
Discount Rate = 8.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.20 | Cagr: 0.35%
[DCF] Terminal Value 80.44% ; FCFF base≈467.6m ; Y1≈314.0m ; Y5≈150.2m
[DCF] Fair Price = N/A (negative equity: EV 4.55b - Net Debt 5.87b = -1.33b; debt exceeds intrinsic value)
EPS Correlation: 68.84 | EPS CAGR: 6.28% | SUE: 0.82 | # QB: 0
Revenue Correlation: -88.62 | Revenue CAGR: -2.58% | SUE: 2.64 | # QB: 4
EPS current Quarter (2026-06-30): EPS=1.12 | Chg30d=-4.01% | Revisions=-57% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.14 | Chg30d=-3.19% | Revisions=-57% | Analysts=12
EPS current Year (2026-12-31): EPS=4.49 | Chg30d=+1.79% | Revisions=+33% | GrowthEPS=+6.9% | GrowthRev=-1.4%
EPS next Year (2027-12-31): EPS=4.81 | Chg30d=+0.92% | Revisions=+38% | GrowthEPS=+7.0% | GrowthRev=+1.1%
[Analyst] Revisions Ratio: -57%